Real-time detection of targeted contrast agent binding is challenging due to background signal from unbound agent. (19)F diffusion weighted MR spectroscopy (DWS) could selectively detect binding of angiogenesis-targeted perfluorocarbon nanoparticles in vivo. Transgenic K14-HPV16 mice with epidermal squamous carcinomas exhibiting up-regulated neovasculature were used, with nontransgenic littermates as controls. Mice were treated with alpha(v)beta(3)-integrin targeted perfluorocarbon nanoparticles. (19)F DWS (b-values from 0 to 16,000 s/mm(2)) was performed on mouse ears in vivo at 11.74 Tesla. Progressive decay of (19)F signal with increased diffusion weighting at low b-values (< 1500 s/mm(2)) was observed in ears of both K14-HPV16 and control mice, demonstrating suppression of background (19)F signal from unbound nanoparticles in the blood. Much of the (19)F signal from ears of K14-HPV16 mice persisted at high b-values, indicating a stationary signal source, reflecting abundant nanoparticle binding to angiogenesis. (19)F signal in controls decayed completely at high b-values (> 1500 s/mm(2)), reflecting a moving signal source due to absence of angiogenesis (no binding sites). Estimated ADCs of nanoparticles in K14-HPV16 and control mice were 33.1 +/- 12.9 microm(2)/s and 19563 +/- 5858 microm(2)/s (p < 0.01). In vivo (19)F DWS can be used for specific detection of bound perfluorocarbon nanoparticles by selectively suppressing background (19)F signal from nanoparticles flowing in blood.
No takes yet. Share an insight, caveat, or question.
Waters et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: